Drugs / AVANZ MITE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT01568190 | Dec 2011 → Jul 2012 | perennial allergic rhinitis | ALK-Abelló A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVANZ MITE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01568190 ↗ |
| Route | Subcutaneous | “Immunologically enhanced subcutaneous specific immunotherapy (SCIT)” PMID 25898693 ↗ 2015 |